Worldwide Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: An International Survey.
COVID-9
immunomodulatory therapy
inflammatory bowel disease
management
pandemic
Journal
Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162
Informations de publication
Date de publication:
17 05 2021
17 05 2021
Historique:
received:
17
06
2020
pubmed:
15
8
2020
medline:
28
5
2021
entrez:
15
8
2020
Statut:
ppublish
Résumé
Persons with inflammatory bowel disease (IBD) may be particularly vulnerable to COVID-19 either because of their underlying disease or its management. Guidance has been presented on the management of persons with IBD in the time of this pandemic by different groups. We aimed to determine how gastroenterologists around the world were approaching the management of IBD. Members of the World Gastroenterology Organization (WGO) IBD Task Force contacted colleagues in countries largely beyond North America and Europe, inviting them to review the WGO website for IBD and COVID-19 introduction, with links to guideline documents, and then to respond to 9 ancillary open-ended management questions. Fifty-two gastroenterologists from 33 countries across 6 continents completed the survey (April 14 to May 16, 2020). They were all adhering for the most part to published guidelines on IBD management in the COVID-19 era. Some differences and reductions in services related to access, and some related to approach within their communities in terms of limiting virus spread. In particular, most gastroenterologists reduced in-person clinics (43 of 52), limited steroid use (47 of 51), limited elective endoscopy (45 of 52), and limited elective surgeries (48 of 51). If a patient was diagnosed with COVID-19, immunomodulatory therapy was mostly held. In most countries, the COVID-19 pandemic significantly altered the approach to persons with IBD. The few exceptions were mostly based on low burden of COVID-19 in individual communities. Regardless of resources or health care systems, gastroenterologists around the world took a similar approach to the management of IBD.
Sections du résumé
BACKGROUND AND AIMS
Persons with inflammatory bowel disease (IBD) may be particularly vulnerable to COVID-19 either because of their underlying disease or its management. Guidance has been presented on the management of persons with IBD in the time of this pandemic by different groups. We aimed to determine how gastroenterologists around the world were approaching the management of IBD.
METHODS
Members of the World Gastroenterology Organization (WGO) IBD Task Force contacted colleagues in countries largely beyond North America and Europe, inviting them to review the WGO website for IBD and COVID-19 introduction, with links to guideline documents, and then to respond to 9 ancillary open-ended management questions.
RESULTS
Fifty-two gastroenterologists from 33 countries across 6 continents completed the survey (April 14 to May 16, 2020). They were all adhering for the most part to published guidelines on IBD management in the COVID-19 era. Some differences and reductions in services related to access, and some related to approach within their communities in terms of limiting virus spread. In particular, most gastroenterologists reduced in-person clinics (43 of 52), limited steroid use (47 of 51), limited elective endoscopy (45 of 52), and limited elective surgeries (48 of 51). If a patient was diagnosed with COVID-19, immunomodulatory therapy was mostly held.
CONCLUSIONS
In most countries, the COVID-19 pandemic significantly altered the approach to persons with IBD. The few exceptions were mostly based on low burden of COVID-19 in individual communities. Regardless of resources or health care systems, gastroenterologists around the world took a similar approach to the management of IBD.
Identifiants
pubmed: 32793973
pii: 5892568
doi: 10.1093/ibd/izaa202
pmc: PMC7454666
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
836-847Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK042086
Pays : United States
Investigateurs
M Masudur Rahman
(MM)
Mostafa N Mohsin
(MN)
Andrea Vieira
(A)
Nayara Carvalho Salgado
(NC)
Marta Brenner Machado
(MB)
Hao Wu
(H)
Joyce W Y Mak
(JWY)
Ying-Lei Miao
(YL)
Murdani Abdullah
(M)
Yehuda Chowers
(Y)
Elly Ogutu
(E)
Smita Devani
(S)
Suk-Kyun Yang
(SK)
Mahmoud Omar
(M)
K L Goh
(KL)
Ida Hilmi
(I)
Raja Affendi Raja Ali
(RA)
Than Than Aye
(TT)
Tin Moe Wai
(TM)
Neeraj Joshi
(N)
Zaigham Abbas
(Z)
Fernando Magro
(F)
Jose Sollano
(J)
Esther A Torres
(EA)
Syed Adnan Mohiuddin
(SA)
Mircea Diculescu
(M)
Majid Almadi
(M)
David Ong
(D)
Gillian Watermeyer
(G)
Navarathne Metthananda
(N)
Shuchen Wei
(S)
Julajak Limsrivilai
(J)
Nonthalee Pausawasdi
(N)
Pises Pisepongsa
(P)
Gursimran Kochhar
(G)
Ximena Rodríguez
(X)
Dao Viet
(D)
Informations de copyright
© 2020 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Gastroenterology. 2020 Sep;159(3):1137-1140.e2
pubmed: 32389667
Clin Gastroenterol Hepatol. 2020 Jun;18(7):1636-1637
pubmed: 32205220
Clin Gastroenterol Hepatol. 2020 May;18(6):1252-1260
pubmed: 32007542
Gastroenterology. 2020 Jul;159(1):14-19.e3
pubmed: 32360567
Gastroenterology. 2020 Aug;159(2):775-777
pubmed: 32283101
Gastroenterology. 2020 Aug;159(2):481-491.e3
pubmed: 32425234
Gastroenterology. 2012 Jan;142(1):46-54.e42; quiz e30
pubmed: 22001864
Lancet. 2018 Dec 23;390(10114):2769-2778
pubmed: 29050646
Gastroenterology. 2020 Jul;159(1):320-334.e27
pubmed: 32407808
Gastroenterology. 2020 Jul;159(1):350-357
pubmed: 32283100
Clin Gastroenterol Hepatol. 2020 Feb;18(2):304-312
pubmed: 31252191